NCT06552858View on ClinicalTrials.gov

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

January 31, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Fluzoparib

150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.

DRUG

Dalpiciclib

150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.

Trial Locations (1)

200000

Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06552858 - Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter